Results 101 to 110 of about 655,557 (182)

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Evolution of BTK inhibitors [PDF]

The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL).
Mathew, Dena
core   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

Building an Interleukin‐10‐Producing Identity: How B Cells Acquire Interleukin‐10 Competence and How Plasma Cell Differentiation Consolidates This Program

Immunological Reviews, Volume 343, Issue 1, October 2026.
ABSTRACT Interleukin (IL)‐10‐producing B cells represent an archetype for the regulatory functions of B cells. Here, we review the cell‐surface receptors and transcriptional regulators that control IL‐10 expression in B cells and enable their regulatory function in vivo.
Bui Thi Cuc, Yanli Tong, Zhiguo Wu, Daniel Alvarez‐Simon, Simon Fillatreau   +4 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy

Frontiers in Endocrinology
IntroductionBruton’s tyrosine kinase (BTK) and interleukin (IL)-2 Inducible T-cell Kinase (ITK) inhibitors have anti-inflammatory properties. We investigated the therapeutic effect of ibrutinib, an orally bioavailable BTK/ITK inhibitor, in a mouse model ...
Charm Kim, Jin Hwan Park, Yeon Jeong Choi, Hyung Oh Jun, Jin Kwon Chung, Tae Kwann Park, Jin Sook Yoon, Jae Wook Yang, Sun Young Jang   +8 more
doaj   +1 more source

Remibrutinib as a Therapeutic Option for Solar Urticaria

Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares, Manoj Bhagwat, Johanna Gonzalez, Vignesh Ramachandran   +3 more
wiley   +1 more source

Combinations of a btk inhibitor and fluorouracil for treating cancers

, 2014
The present application describes therapies for the effective treatment of colon and colorectal carcinomas. The present invention relates to a pharmaceutical kit, comprising combinations of a BTK inhibitor and fluorouracil, for the treatment of colon and
Masiero L, Romano G, Pisano F, Lavitrano M, Giovannoni R, Grassilli E, Cerrito MG   +6 more
core  

Schematic summarizing the proposed mechanisms of PI3Kδ and BTK inhibitor resistance.

, 2017
Upon antigen binding to the B-cell receptor (BCR), the PI3K, MAPK and NF-kB pathways are activated through a cascade of phosphorylation events. BCR stimulation recruits SYK to the membrane, where it is phosphorylated and then subsequently phosphorylates ...
Rick A. Sorensen (3727219), Stacey L. Tannheimer (3727222), Sarah A. Meadows (2495770), Kathleen S. Keegan (1816903), Guang Chen (25155), Robert Brockett (3727216), Zhi-Hua Cui (3722785), Anella Yahiaoui (3722788), Li Li (14993), Christophe Quéva (3727225)   +9 more
core   +1 more source